RESOURCE FOR NONHUMAN PRIMATE IMMUNE REAGENTS

非人灵长类免疫试剂资源

• 批准号: 8357386
• 负责人: Francois J Villinger
• 金额: $ 7.43万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357386
• 关键词: Biological; CD4 Positive T Lymphocytes; Calendar; Cataloging; Catalogs; Cells; Cercocebus atys; Code; Complementary DNA; Drug Kinetics; Funding; Grant; Granulocyte-Macrophage Colony-Stimulating Factor; IL12B gene; Immune; Immune response; Interferon Type II; Interferons; Interleukin-15; Interleukin-17; Interleukin-7; Macaca mulatta; Modeling; National Center for Research Resources; Outcome; Potassium Channel Blockers; Primates; Principal Investigator; Production; RANTES; Reagent; Recombinant Proteins; Research; Research Infrastructure; Research Personnel; Resources; SIV; Source; Spliced Genes; TNFSF4 gene; Testing; United States National Institutes of Health; Variant; Viral; cost; cytokine; expression cloning; in vivo; interleukin-23; nonhuman primate

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This project serves as a resource for the testing, optimization of use and distribution of nonhuman primate specific immune related reagents. Therefore, cDNA coding for various nonhuman primate cytokines have been and continue to be cloned and sequenced. During the past year, the genes and splice variants for PD-1, PD-L1, PD-L2, OX40L, MIP3a, IL-17, IL-23, 4-1BBL, CD24 and IL-15Ra have been added to the catalogue of Old-World NHP cDNAs available. In addition, the production of select nonhuman primate recombinant proteins such as rMamu RANTES, IFN-a, IFN-g, GM-CSF, soluble PD1, IL-7, 10 and 15 has been ongoing. Within the calendar year, the Resource has provided a total of 54 reagents to 20 investigators. These reagents included 33 cDNA or expression clones, 23 orders of cytokine recombinant proteins in varying amounts and 1 order of transfected cell producing rMamu IL-12B. Several additional studies were done in part or fully by this resource: The pharmacokinetics and biological activity of select potassium channels blockers Pap-1, Shk(l)5 and TRAM-34 were tested in vivo. The administration of IL-15 and IL-7 in uninfected and SIV infected rhesus macaques was tested for the delineation of these cytokine's influence on viral replication and immune responses in vivo. In addition, this resource has tested the depletion of CD4+ T cells from sooty mangabeys to study the immunological outcome of such depletion in vivo, as well as the potential benefit of rIL-7 therapy in restoring the CD4 compartment in this model.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 该项目作为非人灵长类特异性免疫相关试剂的测试、优化使用和分配的资源。因此，编码各种非人灵长类细胞因子的cDNA已经并将继续被克隆和测序。去年，PD-1、PD-L1、PD-L2、OX40L、MIP3a、IL-17、IL-23、4-1BBL、CD24 和 IL-15Ra 的基因和剪接变体已添加到目录中可用的旧世界 NHP cDNA。此外，精选非人灵长类重组蛋白（例如 rMamu RANTES、IFN-a、IFN-g、GM-CSF、可溶性 PD1、IL-7、10 和 15）的生产仍在进行中。 年内，资源中心共为 20 名研究人员提供了 54 种试剂。这些试剂包括 33 个 cDNA 或表达克隆、23 个不同数量的细胞因子重组蛋白和 1 个产生 rMamu IL-12B 的转染细胞。部分或全部通过该资源完成了其他几项研究：在体内测试了选定的钾通道阻滞剂 Pap-1、Shk(1)5 和 TRAM-34 的药代动力学和生物活性。在未感染和 SIV 感染的恒河猴中施用 IL-15 和 IL-7 进行了测试，以描述这些细胞因子对体内病毒复制和免疫反应的影响。 此外，该资源还测试了乌白白眉猴 CD4+ T 细胞的消耗，以研究体内这种消耗的免疫学结果，以及 rIL-7 疗法在恢复该模型中 CD4 区室方面的潜在益处。